Drug Profile
Research programme: protein kinase inhibitors - Takeda
Latest Information Update: 16 Jan 2019
Price :
$50
*
At a glance
- Originator Janssen Pharmaceutica; Ortho-McNeil Pharmaceutical
- Developer Shire-Movetis NV
- Class
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diarrhoea
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 16 Jul 2016 No recent reports of development identified for research development in Diarrhoea in Belgium
- 16 Sep 2010 Early research in Diarrhoea in Belgium (unspecified route)